MK-677 (Ibutamoren) occupies a unique position in the growth hormone secretagogue landscape: it is the only orally bioavailable GH secretagogue with substantial human clinical data, making it one of the most studied and discussed compounds in research communities focused on the GH/IGF-1 axis.
What Is MK-677?
MK-677 (also known as Ibutamoren or Nutrobal) is a non-peptide ghrelin receptor agonist and growth hormone secretagogue. Unlike peptide-based GH secretagogues (ipamorelin, GHRP-6, CJC-1295) that require injection, MK-677 is orally active — a critical distinction that drove significant clinical research interest. It was developed by Merck and has been studied in Phase I–III clinical trials for muscle wasting, GH deficiency, osteoporosis, and Alzheimer’s disease.
Mechanism of Action
MK-677 mimics ghrelin at the GH secretagogue receptor (GHSR-1a) in the pituitary gland and hypothalamus, stimulating GH release through the same pathway as endogenous ghrelin. Unlike ghrelin itself, MK-677 does not significantly affect cortisol or prolactin at standard research doses, and it does not meaningfully increase appetite in most human studies — though some individuals report mild hunger increases.
Key downstream effects: elevated GH pulse amplitude and frequency, sustained IGF-1 elevation (the primary mediator of GH’s anabolic effects), and activation of the GH/IGF-1 axis across multiple tissues.
Human Clinical Research Findings
IGF-1 Elevation: Multiple trials show MK-677 produces dose-dependent, sustained increases in IGF-1 — with 25mg daily producing IGF-1 elevations of 60–80% above baseline sustained over months of continuous use. This is among the most robust and consistent findings in any GH secretagogue research.
Muscle Mass: A double-blind trial in healthy elderly subjects showed MK-677 significantly increased lean body mass and reduced fat mass vs. placebo over 12 months. A trial in hip fracture patients showed accelerated muscle mass recovery.
Bone Density: Studies in postmenopausal women and older adults show MK-677 increases bone mineral density over 12–24 months of treatment — consistent with GH/IGF-1’s known role in bone remodeling.
Sleep Quality: MK-677 increases slow-wave sleep (SWS) duration — the stage of sleep when the majority of natural GH pulsatile release occurs. Subjects reported improved sleep quality in trials.
Muscle Wasting: In diet-induced catabolism studies, MK-677 completely reversed nitrogen wasting and prevented the decline in IGF-1 associated with caloric restriction — suggesting anti-catabolic effects relevant to injury recovery and aging research.
MK-677 vs. Injectable GH Secretagogues
| Feature | MK-677 | CJC-1295 + Ipamorelin |
|---|---|---|
| Administration | Oral (once daily) | Injectable |
| Half-life | ~24 hours | Variable (30 min to 8 days) |
| Human trial data | Extensive (Phase I–III) | Phase I–II |
| IGF-1 elevation | 60–80% above baseline (sustained) | Variable, pulsatile |
| GH pulse pattern | More sustained (less pulsatile) | More physiological pulsatility |
Research Considerations
MK-677 has a well-documented side effect profile in trials: transient increases in fasting glucose and insulin resistance (consistent with GH’s counter-regulatory effects on insulin), mild fluid retention, and occasional increased appetite. These effects are generally dose-dependent and reversible. Long-term cardiovascular and oncological safety data beyond 2 years remains limited.
MK-677 is not approved by any regulatory agency for human therapeutic use and is sold strictly for research purposes.
Conclusion
MK-677’s oral bioavailability, extensive human clinical data, and sustained IGF-1 elevation profile make it one of the most comprehensively studied GH secretagogues in the research literature. For researchers studying the GH/IGF-1 axis, body composition, bone biology, or sleep architecture, MK-677 represents a uniquely accessible research tool. Combat Research provides pharmaceutical-grade MK-677 for research applications, independently verified for purity.
For research purposes only. Not for human therapeutic use.
Related Research Articles
Shop MK-677 at Combat Research
Research-grade MK-677 (Ibutamoren) available in oral capsule and injectable formats. ≥99% purity, third-party verified.
